Xencor, Inc Investment Income, Interest
Xencor, Inc (XNCR) reported Investment Income, Interest of $4.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- Xencor, Inc investment income, interest for the quarter ending 2026-06-30 was $4.80M, a 33.77% decline year-over-year.
- Xencor, Inc investment income, interest for the quarter ending 2026-03-31 was $5.46M, a 27.58% decline year-over-year.
- Xencor, Inc investment income, interest for the quarter ending 2025-12-31 was $6.20M, a 24.06% decline year-over-year.
- Xencor, Inc investment income, interest for the quarter ending 2025-09-30 was $6.54M, a 13.25% decline year-over-year.
- Xencor, Inc investment income, interest for fiscal 2025 was $27.52M, a 13.80% decline from fiscal 2024.
- Xencor, Inc investment income, interest for fiscal 2024 was $31.93M, a 65.18% increase from fiscal 2023.
- Xencor, Inc investment income, interest for fiscal 2023 was $19.33M, a 300.23% increase from fiscal 2022.
- Xencor, Inc investment income, interest for fiscal 2022 was $4.83M, a 460.32% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.80M 10-Q · filed 2026-08-05 | $10.26M 10-Q · filed 2026-08-05 | $16.46M derived: sum of 3 quarters · filed 2026-08-05 | $23.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.46M 10-Q · filed 2026-05-06 | $11.66M derived: sum of 2 quarters · filed 2026-05-06 | $18.20M derived: sum of 3 quarters · filed 2026-05-06 | $25.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.74M derived: sum of 2 quarters · filed 2026-02-25 | $19.99M derived: sum of 3 quarters · filed 2026-08-05 | $27.52M 10-K · filed 2026-02-25 |
| 2025-09-30 | $6.54M 10-Q · filed 2025-11-05 | $13.79M derived: sum of 2 quarters · filed 2026-08-05 | $21.32M 10-Q · filed 2025-11-05 | $29.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.25M 10-Q · filed 2026-08-05 | $14.79M 10-Q · filed 2026-08-05 | $22.95M derived: sum of 3 quarters · filed 2026-08-05 | $30.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $7.54M 10-Q · filed 2026-05-06 | $15.70M derived: sum of 2 quarters · filed 2026-05-06 | $23.24M derived: sum of 3 quarters · filed 2026-05-06 | $30.92M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $8.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.70M derived: sum of 2 quarters · filed 2026-02-25 | $23.38M derived: sum of 3 quarters · filed 2026-02-25 | $31.93M 10-K · filed 2026-02-25 |
| 2024-09-30 | $7.54M 10-Q · filed 2025-11-05 | $15.22M derived: sum of 2 quarters · filed 2025-11-05 | $23.77M 10-Q · filed 2025-11-05 | $31.40M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $7.68M 10-Q · filed 2025-08-06 | $16.23M 10-Q · filed 2025-08-06 | $23.87M derived: sum of 3 quarters · filed 2026-02-25 | $28.89M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $8.55M 10-Q · filed 2025-05-07 | $16.19M derived: sum of 2 quarters · filed 2026-02-25 | $21.21M derived: sum of 3 quarters · filed 2026-02-25 | $24.98M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $7.64M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $12.66M derived: sum of 2 quarters · filed 2026-02-25 | $16.43M derived: sum of 3 quarters · filed 2026-02-25 | $19.33M 10-K · filed 2026-02-25 |
| 2023-09-30 | $5.02M 10-Q/A · filed 2025-02-24 | $8.79M derived: sum of 2 quarters · filed 2025-02-24 | $11.69M 10-Q/A · filed 2025-02-24 | |
| 2023-06-30 | $3.77M 10-Q/A · filed 2025-02-24 | $6.67M 10-Q/A · filed 2025-02-24 | ||
| 2023-03-31 | $2.90M 10-Q/A · filed 2025-02-24 | |||
| 2022-12-31 | $4.83M 10-K/A · filed 2025-02-24 | |||
| 2021-12-31 | $862.00K 10-K/A · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |